m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00268)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
GSK3B
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | B16-OVA cell line | Mus musculus |
Treatment: shFTO B16-OVA cells
Control: shNC B16-OVA cells
|
GSE154952 | |
Regulation |
|
logFC: 6.35E-01 p-value: 1.84E-09 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | FTO expression significantly contributes to the phenotype conversion of VSMCs and the aortic dissecting aneurysm by the demethylation function (m6A), thereby providing a novel therapeutic target. Knockdown of FTO suppresses the Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) levels and Klf5 expression regardless of AngII treatment. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Aortic aneurysm or dissection | ICD-11: BD50 | ||
Pathway Response | Nucleotide excision repair | hsa03420 | ||
Cell Process | DNA repair | |||
Cell proliferation and migration | ||||
In-vitro Model | VSMC (Human aortic vascular smooth muscle cells) | |||
Methyltransferase-like 14 (METTL14) [WRITER]
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14 | ||
Cell Line | BMDM | Mus musculus |
Treatment: METTL14 knockout mice BMDM
Control: Wild type mice BMDM
|
GSE153512 | |
Regulation |
|
logFC: 1.08E+00 p-value: 1.69E-24 |
More Results | Click to View More RNA-seq Results |
In total 3 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Responsed Drug | Pertuzumab | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Responsed Drug | Trastuzumab | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Responsed Drug | Tucatinib | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Breast cancer [ICD-11: 2C60]
In total 3 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Pertuzumab | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Trastuzumab | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Experiment 3 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Tucatinib | Approved | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Aortic aneurysm or dissection [ICD-11: BD50]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | FTO expression significantly contributes to the phenotype conversion of VSMCs and the aortic dissecting aneurysm by the demethylation function (m6A), thereby providing a novel therapeutic target. Knockdown of FTO suppresses the Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) levels and Klf5 expression regardless of AngII treatment. | |||
Responsed Disease | Aortic aneurysm or dissection [ICD-11: BD50] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Pathway Response | Nucleotide excision repair | hsa03420 | ||
Cell Process | DNA repair | |||
Cell proliferation and migration | ||||
In-vitro Model | VSMC (Human aortic vascular smooth muscle cells) | |||
Pertuzumab
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Trastuzumab
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
Tucatinib
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | m6A-hypomethylation regulated FGFR4 phosphorylates Glycogen synthase kinase-3 beta (GSK3Beta/GSK3B) and activates beta-catenin/TCF4-SLC7A11/FPN1 signaling to drive anti-HER2 resistance. Knockdown of METTL14 significantly increased the expression level of FGFR4 in HER2-positive breast cancer cells. FGFR4 reduced the sensitivity of HER2-positive breast cancer to trastuzumab plus pertuzumab or tucatinib. These results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer. | |||
Target Regulator | Methyltransferase-like 14 (METTL14) | WRITER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | Wnt signaling pathway | hsa04310 | ||
Cell Process | Glutathione synthesis | |||
In-vitro Model | ZR-75-1 | Invasive breast carcinoma | Homo sapiens | CVCL_0588 |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
SUM-159 (A mesenchymal triple-negative breast cancer cell line) | ||||
SK-BR-3 | Breast adenocarcinoma | Homo sapiens | CVCL_0033 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | |
MDA-MB-361 | Breast adenocarcinoma | Homo sapiens | CVCL_0620 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MCF-10A | Normal | Homo sapiens | CVCL_0598 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
BT-549 | Invasive breast carcinoma | Homo sapiens | CVCL_1092 | |
BT-474 | Invasive breast carcinoma | Homo sapiens | CVCL_0179 | |
AU565 | Breast adenocarcinoma | Homo sapiens | CVCL_1074 | |
In-vivo Model | Luciferase-labeled rSKBR3 and MDA-MB-361 cells (1 × 107 cells) mixed with 1:1 Matrigel (Corning, 356237) were subcutaneously injected into the fat pads of mice. After a tumor was palpable, the mice were randomized into four groups (five mice per group), and they were treated with vehicle, trastuzumab (20 mg/kg, intraperitoneal administration), roblitinib (30 mg/kg, oral administration), or a combination of both drugs. | |||
References